Renova’s Gene Therapy To Reverse Heart Remodeling In CHF
This article was originally published in The Pink Sheet Daily
Executive Summary
Reversing the “remodeling” of the heart in congestive heart failure with an investigational gene therapy is one of the aims of the San Diego-based biotech that is planning late-stage clinical development.
You may also be interested in...
Gene Therapy: Cures Within Reach
After rocky beginnings, there is increasing optimism about the potential for gene therapy to make an impact in rare disease. Promising data from late-stage clinical trials, improved safety, and the first Western regulatory approval of a gene therapy are now driving numerous initial public offerings, venture capital financings, and tie-ups with major pharmaceutical companies.
At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use
At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.